Meeting
2016 Gastrointestinal Cancers Symposium
Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer.
Authors
Hyun Cheol Chung
Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University Health System, Sinchon-dong, South Korea
Hyun Cheol Chung , Hendrik-Tobias Arkenau , Lucjan Wyrwicz , Do-Youn Oh , Keun-Wook Lee , Jeffrey R. Infante , Kevin M. Chin , Anja von Heydebreck , Yoon-Koo Kang , Howard Safran
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01772004
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 167)
DOI
10.1200/jco.2016.34.4_suppl.167
Abstract #
167
Poster Bd #
N15
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in Japanese patients with advanced gastric or gastroesophageal junction cancer.
First Author: Tomohiro Nishina
Poster
2016 Gastrointestinal Cancers Symposium
Avelumab (MSB0010718C), an anti-PD-L1 antibody, as a third-line treatment in patients with advanced gastric or gastroesophageal junction cancer: A phase Ib JAVELIN Solid Tumor trial.
First Author: Do-Youn Oh
Poster
2016 Genitourinary Cancers Symposium
Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial.
First Author: Andrea B. Apolo
Poster
2016 ASCO Annual Meeting
Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase 1b trial: Safety, clinical activity, and PD-L1 expression.
First Author: Claire F. Verschraegen